Truist initiated coverage on Insmed with a new price target
$INSM
Biotechnology: Pharmaceutical Preparations
Health Care
Truist initiated coverage of Insmed with a rating of Buy and set a new price target of $48.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | Outperform | William Blair | |
| 8/13/2025 | $126.00 | Overweight → Equal-Weight | Morgan Stanley |
| 5/13/2025 | $105.00 | Buy | Jefferies |
| 2/25/2025 | $100.00 | Outperform | RBC Capital Mkts |
| 4/23/2024 | $48.00 | Buy | Truist |
| 2/15/2024 | $42.00 | Outperform | Wolfe Research |
| 12/8/2023 | $55.00 | Overweight | Wells Fargo |
| 11/20/2023 | $36.00 | Overweight | JP Morgan |
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
4 - INSMED Inc (0001104506) (Issuer)
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic Inflammation — BRINSUPRI Was Reviewed Under CHMP's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health and Therapeutic Innovation — BRIDGEWATER, N.J., Oct. 17, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europe
—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patients with Non-Cystic Fibrosis Bronchiectasis— BRIDGEWATER, N.J., Oct. 16, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from the Phase 3 ASPEN study of BRINSUPRI™ (brensocatib) at CHEST 2025, the American College of Chest Physicians Annual Meeting, taking place October 19 - Oc
BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 30, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing ac
William Blair initiated coverage of Insmed with a rating of Outperform
Morgan Stanley downgraded Insmed from Overweight to Equal-Weight and set a new price target of $126.00
Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00
4 - INSMED Inc (0001104506) (Issuer)
SCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
SCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)
144 - INSMED Inc (0001104506) (Subject)
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling
PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS
—Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year
BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti
SC 13G/A - INSMED Inc (0001104506) (Subject)
SC 13G - INSMED Inc (0001104506) (Subject)
SC 13G/A - INSMED Inc (0001104506) (Subject)
BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2025 financial results on Thursday, October 30, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 30, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing ac
— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET — BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious
BRIDGEWATER, N.J., July 24, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 7, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing acces